DexCom, Inc. (DXCM) Quick Ratio (Acid-Test): 1.59
Is DexCom, Inc.’s quick ratio (acid-test) high or low?
DexCom, Inc.'s quick ratio (acid-test) of 1.59 is 44% below its 5-year average of 2.83, near the low end of its 5-year range (1.28–5.19).
The quick ratio (acid-test) for DexCom, Inc. (DXCM) is 1.59 as of Wednesday, June 10, 2026. It is above its 12-month average by 10.80% (1.44).
DXCM Quick Ratio (Acid-Test) Chart
DXCM Average Quick Ratio (Acid-Test) Chart
DXCM Current vs Average Quick Ratio (Acid-Test) Chart
DXCM Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
1.59
QUICK RATIO (ACID-TEST) AVG TTM
1.44
QUICK RATIO (ACID-TEST) AVG 3Y
1.80
QUICK RATIO (ACID-TEST) AVG 5Y
2.83
QUICK RATIO (ACID-TEST) AVG 10Y
3.61
QUICK RATIO (ACID-TEST) AVG 15Y
3.72
QUICK RATIO (ACID-TEST) AVG 20Y
4.24
CURRENT VS TTM AVG
+10.80%
CURRENT VS 3Y AVG
-11.42%
CURRENT VS 5Y AVG
-43.85%
CURRENT VS 10Y AVG
-55.94%
CURRENT VS 15Y AVG
-57.23%
CURRENT VS 20Y AVG
-62.49%
DXCM Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $29.24B | 1.59 | 1.44 | 1.80 | 2.83 |
| Biogen Inc. (BIIB) | $29.00B | 2.03 | 1.46 | 1.69 | 1.64 |
| IQVIA Holdings Inc. (IQV) | $30.60B | 0.75 | 0.79 | 0.83 | 0.90 |
| Medline Inc. (MDLN) | $30.90B | 2.37 | 1.97 | 2.09 | 2.09 |
| Veeva Systems Inc. (VEEV) | $26.73B | 4.89 | 4.70 | 4.39 | 4.08 |
| Centene Corporation (CNC) | $31.94B | 1.68 | 1.40 | 1.24 | 1.19 |
| Zoetis Inc. (ZTS) | $34.20B | 1.94 | 1.51 | 1.66 | 1.96 |
| Waters Corporation (WAT) | $23.83B | 1.27 | 1.39 | 1.50 | 1.54 |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 0.81 | 0.77 | 0.77 | 0.79 |
| BioNTech SE (BNTX) | $21.81B | 7.49 | 7.42 | 7.84 | 6.36 |
Liquidity Comparison
Quick Ratio
1.59
Excludes inventory
Current Ratio
1.88
Includes inventory
DexCom, Inc. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for DexCom, Inc. (DXCM)?
- The quick ratio (acid-test) for DXCM stock is 1.59.
- Is DexCom, Inc.'s quick ratio (acid-test) high or low?
- DexCom, Inc.'s quick ratio (acid-test) of 1.59 is 44% below its 5-year average of 2.83, near the low end of its 5-year range (1.28–5.19).
- What is the TTM average quick ratio (acid-test) for DexCom, Inc. (DXCM)?
- The TTM average quick ratio (acid-test) for DXCM stock is 1.44.
- What is the 3Y average quick ratio (acid-test) for DexCom, Inc. (DXCM)?
- The 3Y average quick ratio (acid-test) for DXCM stock is 1.80.
- What is the 5Y average quick ratio (acid-test) for DexCom, Inc. (DXCM)?
- The 5Y average quick ratio (acid-test) for DXCM stock is 2.83.
- What is the 10Y average quick ratio (acid-test) for DexCom, Inc. (DXCM)?
- The 10Y average quick ratio (acid-test) for DXCM stock is 3.61.
- What is the 15Y average quick ratio (acid-test) for DexCom, Inc. (DXCM)?
- The 15Y average quick ratio (acid-test) for DXCM stock is 3.72.
- What is the 20Y average quick ratio (acid-test) for DexCom, Inc. (DXCM)?
- The 20Y average quick ratio (acid-test) for DXCM stock is 4.24.
DexCom, Inc. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 1.59 |
| 2024-12-31 | 1.28 |
| 2023-12-31 | 2.48 |
| 2022-12-31 | 1.83 |
| 2021-12-31 | 4.62 |
| 2020-12-31 | 5.19 |
| 2019-12-31 | 5.13 |
| 2018-12-31 | 7.32 |
| 2017-12-31 | 5.04 |
| 2016-12-31 | 2.29 |
| 2015-12-31 | 2.93 |
| 2014-12-31 | 3.20 |
| 2013-12-31 | 2.62 |
| 2012-12-31 | 3.60 |
| 2011-12-31 | 6.53 |
| 2010-12-31 | 3.83 |
| 2009-12-31 | 1.82 |
| 2008-12-31 | 1.97 |
| 2007-12-31 | 7.83 |
| 2006-12-31 | 10.70 |
| 2005-12-31 | 7.21 |
| 2004-12-31 | 17.39 |
| 2003-12-31 | 20.47 |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach